Merck Profit Margin 2006-2019 | MRK

Current and historical gross margin, operating margin and net profit margin for Merck (MRK) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Merck net profit margin as of June 30, 2019 is 21.1%.
Merck Annual Profit Margins
Merck Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $211.513B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $345.150B 15.03
Roche Holding AG (RHHBY) Switzerland $236.204B 0.00
Pfizer (PFE) United States $204.151B 12.02
Novartis AG (NVS) Switzerland $199.581B 17.16
Novo Nordisk (NVO) Denmark $117.216B 20.71
AstraZeneca (AZN) United Kingdom $112.218B 21.71
Sanofi (SNY) France $109.456B 13.45
Eli Lilly (LLY) United States $107.057B 19.98
AbbVie (ABBV) United States $104.248B 8.35
GlaxoSmithKline (GSK) United Kingdom $101.988B 12.82
Bristol-Myers Squibb (BMY) United States $80.856B 11.47
Bayer (BAYRY) Germany $70.165B 10.22
H Lundbeck (HLUYY) Denmark $6.958B 10.04